Sientra, Inc. (SIEN) Shares Sold by Royal Bank of Canada
Royal Bank of Canada lowered its position in Sientra, Inc. (NASDAQ:SIEN) by 81.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,838 shares of the medical instruments supplier’s stock after selling 327,179 shares during the period. Royal Bank of Canada owned about 0.38% of Sientra worth $707,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new stake in Sientra during the second quarter valued at about $101,000. Nationwide Fund Advisors lifted its position in shares of Sientra by 260.4% in the second quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock valued at $107,000 after acquiring an additional 7,921 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 40 shares in the last quarter. Accredited Investors Inc. purchased a new position in shares of Sientra in the second quarter valued at about $115,000. Finally, Highbridge Capital Management LLC purchased a new position in shares of Sientra in the first quarter valued at about $117,000. 77.59% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have recently commented on the company. Canaccord Genuity assumed coverage on Sientra in a research report on Monday, August 28th. They issued a “buy” rating and a $14.00 price objective on the stock. Lake Street Capital restated a “buy” rating and issued a $15.00 price objective (up from $11.00) on shares of Sientra in a research report on Wednesday, August 2nd. Stifel Nicolaus restated a “hold” rating and issued a $14.00 price objective (up from $11.00) on shares of Sientra in a research report on Wednesday, September 27th. William Blair upgraded Sientra from a “market perform” rating to an “outperform” rating in a research report on Wednesday, September 13th. Finally, Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $13.75.
Shares of Sientra, Inc. (NASDAQ SIEN) opened at $13.45 on Thursday. Sientra, Inc. has a 52-week low of $7.02 and a 52-week high of $16.68.
Sientra (NASDAQ:SIEN) last posted its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.06). The firm had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $10.54 million. Sientra had a negative return on equity of 62.14% and a negative net margin of 169.77%. Sientra’s quarterly revenue was up 50.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. equities research analysts predict that Sientra, Inc. will post -3.07 EPS for the current fiscal year.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.